JP7116792B2 - 疼痛を緩和するための組成物および方法 - Google Patents

疼痛を緩和するための組成物および方法 Download PDF

Info

Publication number
JP7116792B2
JP7116792B2 JP2020532541A JP2020532541A JP7116792B2 JP 7116792 B2 JP7116792 B2 JP 7116792B2 JP 2020532541 A JP2020532541 A JP 2020532541A JP 2020532541 A JP2020532541 A JP 2020532541A JP 7116792 B2 JP7116792 B2 JP 7116792B2
Authority
JP
Japan
Prior art keywords
pain
compound
pharmaceutical composition
analgesic
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020532541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533402A5 (enExample
JP2020533402A (ja
Inventor
ニコラス バサン
エルナン バサン
フリオ アルバレス‐ブイラ
デニス ポール
カロリーナ ブルゴス
Original Assignee
ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ
ユニバーシティー オブ アルカラ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ, ユニバーシティー オブ アルカラ filed Critical ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ
Publication of JP2020533402A publication Critical patent/JP2020533402A/ja
Publication of JP2020533402A5 publication Critical patent/JP2020533402A5/ja
Application granted granted Critical
Publication of JP7116792B2 publication Critical patent/JP7116792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020532541A 2017-08-25 2018-03-12 疼痛を緩和するための組成物および方法 Active JP7116792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762550137P 2017-08-25 2017-08-25
US62/550,137 2017-08-25
PCT/US2018/022029 WO2019040122A1 (en) 2017-08-25 2018-03-12 COMPOSITIONS AND METHODS FOR ALLEVIATING PAIN

Publications (3)

Publication Number Publication Date
JP2020533402A JP2020533402A (ja) 2020-11-19
JP2020533402A5 JP2020533402A5 (enExample) 2021-04-15
JP7116792B2 true JP7116792B2 (ja) 2022-08-10

Family

ID=65439193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020532541A Active JP7116792B2 (ja) 2017-08-25 2018-03-12 疼痛を緩和するための組成物および方法

Country Status (16)

Country Link
US (3) US11458142B2 (enExample)
EP (1) EP3672938B1 (enExample)
JP (1) JP7116792B2 (enExample)
KR (1) KR102584483B1 (enExample)
CN (1) CN111278805B (enExample)
AU (1) AU2018319549C1 (enExample)
BR (1) BR112020003705B1 (enExample)
CA (1) CA3073801C (enExample)
ES (1) ES2965542T3 (enExample)
HR (1) HRP20231564T1 (enExample)
HU (1) HUE066993T2 (enExample)
MX (1) MX2020002147A (enExample)
PL (1) PL3672938T3 (enExample)
RS (1) RS65171B1 (enExample)
SM (1) SMT202400050T1 (enExample)
WO (2) WO2019040122A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3073801C (en) 2017-08-25 2023-07-11 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for ameliorating pain
CN113993846A (zh) * 2020-04-15 2022-01-28 诺门图姆股份有限公司 用于治疗疼痛和/或炎症的组合物和方法
CN120936345A (zh) * 2023-03-10 2025-11-11 南方壁垒制药公司 非阿片类药物的纳米颗粒制剂
EP4786458A1 (en) * 2023-09-28 2026-08-05 West China Hospital, Sichuan University Analgesic compound, preparation method therefor, and use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508325A (ja) 2003-10-09 2007-04-05 ザ ファウンデーション フォー ザ エルエスユー ヘルス サイエンス センター 鎮痛性化合物、それらの合成およびそれらを含む薬学的組成物
WO2008021896A2 (en) 2006-08-08 2008-02-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic methods for neuropathic pain
JP2010522242A (ja) 2007-03-23 2010-07-01 ファイザー・リミテッド イオンチャネルの阻害剤
JP2011231094A (ja) 2009-11-02 2011-11-17 Neurotherapeutics Pharma Inc ブメタニド、フロセミド、ピレタニド、アゾセミド、およびトルセミドのアナログ、組成物および使用方法
CN104230762A (zh) 2014-08-28 2014-12-24 青岛农业大学 一种含酰胺基团的苯磺酰胺类化合物及其制备和应用
WO2017034872A1 (en) 2015-08-25 2017-03-02 Janssen Pharmaceutica Nv Indazole derivatives useful as cb-1 inverse agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2822827B1 (fr) 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
EP2389371A4 (en) 2009-01-22 2012-09-12 Neurotherapeutics Pharma Inc ANALOGUES OF BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE AND TORSEMID, AND RELATED COMPOSITIONS AND METHODS OF USE
CA3073801C (en) * 2017-08-25 2023-07-11 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for ameliorating pain
CN108299255B (zh) * 2018-02-11 2020-05-19 山东大学 组蛋白去乙酰化酶8选择性抑制剂及其制备方法和应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508325A (ja) 2003-10-09 2007-04-05 ザ ファウンデーション フォー ザ エルエスユー ヘルス サイエンス センター 鎮痛性化合物、それらの合成およびそれらを含む薬学的組成物
WO2008021896A2 (en) 2006-08-08 2008-02-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic methods for neuropathic pain
JP2010522242A (ja) 2007-03-23 2010-07-01 ファイザー・リミテッド イオンチャネルの阻害剤
JP2011231094A (ja) 2009-11-02 2011-11-17 Neurotherapeutics Pharma Inc ブメタニド、フロセミド、ピレタニド、アゾセミド、およびトルセミドのアナログ、組成物および使用方法
CN104230762A (zh) 2014-08-28 2014-12-24 青岛农业大学 一种含酰胺基团的苯磺酰胺类化合物及其制备和应用
WO2017034872A1 (en) 2015-08-25 2017-03-02 Janssen Pharmaceutica Nv Indazole derivatives useful as cb-1 inverse agonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Archieves of Pharmacal Research，2005年，vol.28, no.6，pp.637-647
Letters in Organic Chemistry，2013年，vol.10，pp.70-76
Organic Process Research & Development，2009年，vol.13, no.4，pp.820-822

Also Published As

Publication number Publication date
MX2020002147A (es) 2022-10-03
EP3672938A4 (en) 2021-04-21
EP3672938B1 (en) 2023-11-01
PL3672938T3 (pl) 2024-06-17
RS65171B1 (sr) 2024-03-29
CN111278805A (zh) 2020-06-12
RU2020110222A (ru) 2021-09-27
CN111278805B (zh) 2023-04-18
US20210379075A1 (en) 2021-12-09
WO2019040122A1 (en) 2019-02-28
AU2018319549A1 (en) 2020-02-20
BR112020003705A2 (pt) 2020-11-17
US20200230087A1 (en) 2020-07-23
HRP20231564T1 (hr) 2024-03-29
KR20200058385A (ko) 2020-05-27
US11007199B2 (en) 2021-05-18
HUE066993T2 (hu) 2024-09-28
US20200179393A1 (en) 2020-06-11
WO2021142282A1 (en) 2021-07-15
EP3672938C0 (en) 2023-11-01
BR112020003705B1 (pt) 2023-02-28
US11529355B2 (en) 2022-12-20
AU2018319549C1 (en) 2023-06-15
RU2020110222A3 (enExample) 2021-09-27
CA3073801C (en) 2023-07-11
KR102584483B1 (ko) 2023-10-05
CA3073801A1 (en) 2019-02-28
SMT202400050T1 (it) 2024-03-13
US11458142B2 (en) 2022-10-04
JP2020533402A (ja) 2020-11-19
AU2018319549B2 (en) 2023-03-16
ES2965542T3 (es) 2024-04-15
EP3672938A1 (en) 2020-07-01

Similar Documents

Publication Publication Date Title
CN104662007B (zh) 胱硫醚‑γ‑裂合酶(CSE)抑制剂
RU2640418C2 (ru) Ингибиторы цистатионин-г-лиазы (cse)
US11529355B2 (en) Compositions and methods for ameliorating pain and reducing fever
CN109843849B (zh) 酰胺化合物、其药物组合物及其使用方法
EP3532065B1 (en) Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof
ES2991820T3 (es) Formulaciones de un inhibidor de la calicreína plasmática
ES2749433T3 (es) Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
JP7830540B2 (ja) ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
JP2025511732A (ja) Ａｔｒ阻害薬の使用方法
CN120393023A (zh) 组合疗法方法、组合物和试剂盒
WO2011112602A1 (en) Analgesic compounds, compositions, and uses thereof
ES2526398T3 (es) Composiciones inhibidoras de la recaptación de serotonina-norepinefrina para tratar el dolor crónico
CN121752275A (zh) 用于治疗或预防痛风的化合物
WO2008145840A2 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere
RU2777368C2 (ru) Композиции и способы для уменьшения боли
FR3077201A1 (fr) Derives aminoacides contenant un groupement disulfanyle sous forme d'un inhibiteur de nep et d'apn pour la prevention et le traitement des douleurs relatives au nerf trijumeau
HK40021798A (en) Compounds for ameliorating pain
HK40021798B (en) Compounds for ameliorating pain
TWI432195B (zh) 神經細胞死亡抑制劑
EA050218B1 (ru) Производные 6-метилурацила, обладающие антихолинэстеразной активностью, и их применение
TW202440571A (zh) 化合物及其用途
HK40050156B (en) Co-crystal of sorafenib derivatives and process for preparation thereof
MXPA06009436A (en) Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210301

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210622

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220517

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220729

R150 Certificate of patent or registration of utility model

Ref document number: 7116792

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250